Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Study Supports Immunotherapy/Radiation Combo in Head and Neck Cancer

April 8th 2016

Jonathan D. Schoenfeld, MD, discusses potential synergy between radiation therapy, given with or without chemotherapy, and immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

Challenging Genomic Blueprint of Head and Neck Cancers Emerges

April 8th 2016

Next-generation sequencing efforts focusing on the most common form, head and neck squamous cell carcinoma, are illuminating the hidden complexities of its genome.

Routine Imaging Not Necessary for HPV-Associated Oropharynx Cancer

April 6th 2016

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

Teaching Points and Conclusions in DTC

April 1st 2016

Emerging Therapies in Differentiated Thyroid Cancer

April 1st 2016

Sequencing in DTC: Lenvatinib and Sorafenib

April 1st 2016

TKI Dose Adjustment in Advanced DTC

April 1st 2016

Safety and Efficacy of Lenvatinib in Advanced DTC

April 1st 2016

Efficacy and Toxicity of Sorafenib in Advanced DTC

April 1st 2016

TKI Therapy for Advanced Thyroid Cancer

April 1st 2016

Systemic Therapy for RAI-Refractory DTC

April 1st 2016

RAI-Refractory Defined

April 1st 2016

Multidisciplinary Care: High-Risk DTC

April 1st 2016

Multidisciplinary Care of Low/Intermediate Risk DTC

April 1st 2016

Moving Toward Personalized Medicine in Advanced DTC

April 1st 2016

Molecular Testing in Thyroid Cancer

April 1st 2016

Initial Workup for Differentiated Thyroid Cancer

April 1st 2016

Expert Projects 2016 FDA Approvals of Nivolumab and Pembrolizumab in Head and Neck Cancer

March 28th 2016

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Mutational Analysis Advances Precision Medicine in Head and Neck Cancer

March 28th 2016

Ezra Cohen, MD, discusses results of a biomarker analysis and the next steps in understanding biomarkers for afatinib in patients with head and neck cancer.

ACS Publishes New Guideline for Head and Neck Cancer Survivorship Care

March 28th 2016

An expert panel has developed clinical practice guidelines for the management of head and neck cancer survivors.